Subclinical Anthracycline Cardiotoxicity in Patients With Acute Promyelocytic Leukemia in Long‐Term Remission After the AIDA Protocol
Open Access
- 9 January 2012
- journal article
- research article
- Published by Wiley in Congestive Heart Failure
- Vol. 18 (4) , 217-221
Abstract
Anthracycline chemotherapy remains a critical component of cancer treatment despite its established risk of cardiotoxicity. To investigate whether the AIDA protocol, which combines idarubicin, mitoxantrone, and all‐trans retinoic acid (ATRA) for treatment of acute promyelocytic leukemia (APL) results in late cardiotoxicity, 34 APL patients in long‐term remission were evaluated. The cumulative dose of idarubicin and mitoxantrone were 80 mg/m2 and 50 mg/m2, respectively. Median follow‐up was 7 years. Segmental wall motion abnormalities (SWMAs) were detected in 11 AIDA patients who still presented with an ejection fraction (EF) within normal limits (EF 56% in the AIDA group vs 59% in the control group, P=.01). However, parameters of diastolic dysfunction were significantly impaired in the AIDA group (E/A ratio: 1.04 in the AIDA group vs 1.28 in the control group, P=.001; E/E’ lateral ratio: 10.04 in the AIDA group vs 5.79 in the control group, P≤.001) as well as left atrial volume (52 mL in the AIDA group vs 35 mL in the control group, P<.001). Cardiac toxicity due to anthracycline therapy is often frequent. Changes in diastolic function are helpful in the detection of subclinical anthracycline cardiotoxicity in long‐term cardiac follow‐up despite a preserved systolic ventricular function.Keywords
This publication has 34 references indexed in Scilit:
- Development of diastolic heart failure in a 6-year follow-up study in patients after acute myocarditisHeart, 2010
- Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline dosesBritish Journal of Haematology, 2010
- Cardiac Functional Evaluation Using Vector Velocity Imaging After Chemotherapy Including Anthracyclines in Children With CancerKorean Circulation Journal, 2009
- Tissue Doppler ImagingJACC, 2007
- Clinical heart failure in a cohort of children treated with anthracyclines: A long-term follow-up studyEuropean Journal of Cancer, 2006
- Restrictive diastolic filling predicts death after acute myocardial infarction: systematic review and meta-analysis of prospective studiesHeart, 2006
- Prospective longitudinal evaluation of doxorubicin‐induced cardiomyopathy in sarcoma patients: A report of the late effects surveillance system (LESS)Pediatric Blood & Cancer, 2005
- Long-Term Prospective Follow-Up Study of Cardiac Function After Cardiotoxic Therapy for Malignancy in ChildrenJournal of Clinical Oncology, 2003
- Echocardiographic evaluation of patients cured of childhood cancer: A single center study of 117 subjects who received anthracyclinesMedical and Pediatric Oncology, 2001
- Cardiac dysfunction late after cardiotoxic therapy for childhood cancerThe American Journal of Cardiology, 1994